Sei Investments Co. Sells 3,606 Shares of Anika Therapeutics, Inc. (NASDAQ:ANIK)

Sei Investments Co. trimmed its holdings in shares of Anika Therapeutics, Inc. (NASDAQ:ANIK) by 12.3% in the second quarter, according to its most recent filing with the SEC. The firm owned 25,712 shares of the biotechnology company’s stock after selling 3,606 shares during the period. Sei Investments Co. owned approximately 0.18% of Anika Therapeutics worth $651,000 as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in the business. Renaissance Technologies LLC boosted its holdings in Anika Therapeutics by 6.9% during the second quarter. Renaissance Technologies LLC now owns 598,229 shares of the biotechnology company’s stock valued at $15,153,000 after purchasing an additional 38,412 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its holdings in Anika Therapeutics by 3.5% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 47,691 shares of the biotechnology company’s stock valued at $1,208,000 after purchasing an additional 1,601 shares during the last quarter. American Century Companies Inc. boosted its position in Anika Therapeutics by 11.8% in the second quarter. American Century Companies Inc. now owns 23,892 shares of the biotechnology company’s stock valued at $605,000 after buying an additional 2,518 shares in the last quarter. Acadian Asset Management LLC grew its stake in Anika Therapeutics by 5.1% during the second quarter. Acadian Asset Management LLC now owns 442,944 shares of the biotechnology company’s stock worth $11,217,000 after buying an additional 21,517 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its holdings in shares of Anika Therapeutics by 20.5% during the second quarter. Bank of New York Mellon Corp now owns 61,480 shares of the biotechnology company’s stock worth $1,557,000 after buying an additional 10,439 shares in the last quarter. 91.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Barrington Research reissued an “outperform” rating and issued a $37.00 target price on shares of Anika Therapeutics in a report on Friday, August 9th.

Anika Therapeutics Stock Up 1.2 %

Shares of NASDAQ ANIK opened at $24.64 on Wednesday. Anika Therapeutics, Inc. has a 12-month low of $17.88 and a 12-month high of $29.11. The firm’s 50-day simple moving average is $25.30 and its 200 day simple moving average is $25.84. The company has a market cap of $359.42 million, a price-to-earnings ratio of -4.69 and a beta of 0.83.

Anika Therapeutics (NASDAQ:ANIK) last released its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.01) EPS for the quarter, missing the consensus estimate of $0.23 by ($0.24). Anika Therapeutics had a negative net margin of 44.45% and a positive return on equity of 0.94%. The company had revenue of $41.92 million for the quarter, compared to the consensus estimate of $39.90 million. During the same period last year, the company earned ($0.06) earnings per share. On average, equities analysts expect that Anika Therapeutics, Inc. will post -0.1 earnings per share for the current year.

Anika Therapeutics Profile

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.